Difference between revisions of "I-123 Biomarker Committee"
Jump to navigation
Jump to search
m |
|||
| (9 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
{{TOCright}} | {{TOCright}} | ||
:Co-chairs: John Dickson, PhD; John Seibyl, MD | :Co-chairs: John Dickson, PhD; John Seibyl, MD | ||
| − | : | + | :RSNA Staff Support: Julie Lisiecki |
| − | * [http://tinyurl.com/QIBA-SPECT-Roster Roster] | + | * [http://tinyurl.com/QIBA-SPECT-I-123-Roster Roster] |
| Line 8: | Line 8: | ||
==Recent Meetings/Call Summaries== | ==Recent Meetings/Call Summaries== | ||
| + | |||
| + | *[[Media:2018_11-16_QIBA_SPECT_I-123_Call Summary-FINAL.pdf | November 16, 2018]] | ||
*[[Media:2018_08-17_QIBA_SPECT_I-123_Call Summary-FINAL.pdf | August 17, 2018]] | *[[Media:2018_08-17_QIBA_SPECT_I-123_Call Summary-FINAL.pdf | August 17, 2018]] | ||
| Line 15: | Line 17: | ||
==Reference Materials== | ==Reference Materials== | ||
| + | |||
| + | *[[Media:QIBA SPECT I-123 BC (11.16.2018).pdf | QIBA SPECT I-123 Biomarker Committee Presentation (11.16.2018)]] ''John Seibyl, MD'' | ||
| + | |||
| + | ==QIBA Funded Projects== | ||
| + | |||
| + | |||
| + | ====Round 6==== | ||
| + | |||
| + | *[[Media:Multi-center Phantom Study to Characterize Bias and Precision of Quantitative I-123 SPECT.pdf | Project (V) Multi-center Phantom Study to Characterize Bias and Precision of Quantitative I-123 SPECT (University of Michigan)]] | ||
| + | |||
| + | *[[Media:I-123 DAT Scan Digital Reference Object Development.pdf | Project (X) I-123 DAT Scan Digital Reference Object Development (University of Washington)]] | ||
Revision as of 16:52, 22 May 2019
- Co-chairs: John Dickson, PhD; John Seibyl, MD
- RSNA Staff Support: Julie Lisiecki
Quantifying Dopamine Transporters with 123Iodine Labeled Ioflupane in Neurodegenerative Diseases
Recent Meetings/Call Summaries
Profile Development
Reference Materials
- QIBA SPECT I-123 Biomarker Committee Presentation (11.16.2018) John Seibyl, MD